Kariv Tomer

CIK 00015680776 companiesFLEMINGTON, NJ

SEC Profile

Transactions

Companies

Filings

CIK

0001568077

Recent Transactions

50 trades

Sale
Keros Therapeutics, Inc.$KROS
Common Stock, $0.0001 par value per share
2025-10-15$17.75/sh−2,284,612→ 0 total
Sale
Keros Therapeutics, Inc.$KROS
Common Stock, $0.0001 par value per share
2025-10-15$17.75/sh−1,121,045→ 0 total
Sale
Keros Therapeutics, Inc.$KROS
Common Stock, $0.0001 par value per share
2025-10-15$17.75/sh−1,226,412→ 0 total
Sale
Keros Therapeutics, Inc.$KROS
Common Stock, $0.0001 par value per share
2025-10-15$17.75/sh−155,262→ 0 total
Award
Keros Therapeutics, Inc.$KROS
Common Stock
2025-06-04+5,250→ 5,250 total
Award
Keros Therapeutics, Inc.$KROS
Stock Option (right to buy)
2025-06-04+10,500→ 10,500 total
Award
Keros Therapeutics, Inc.$KROS
Stock Option (right to buy)
2024-05-30+10,000→ 10,000 total
Award
Keros Therapeutics, Inc.$KROS
Stock Option (right to buy)
2023-06-06+10,000→ 10,000 total
Award
Eloxx Pharmaceuticals, Inc.
Stock Options (Right to Buy)
2023-01-30+2,859→ 2,859 total
Exercise of In-Money
Keros Therapeutics, Inc.$KROS
Common Stock
2022-11-29$0.00/sh−1,723→ 1,121,045 total
Exercise of In-Money
Keros Therapeutics, Inc.$KROS
Call Options (obligation to sell)
2022-11-29−1,914→ 0 total
Exercise of In-Money
Keros Therapeutics, Inc.$KROS
Common Stock
2022-11-29$0.00/sh−3,539→ 2,284,612 total
Exercise of In-Money
Keros Therapeutics, Inc.$KROS
Common Stock
2022-11-29$0.00/sh−1,914→ 1,226,412 total
Exercise of In-Money
Keros Therapeutics, Inc.$KROS
Call Options (obligation to sell)
2022-11-29−1,723→ 0 total
Exercise of In-Money
Keros Therapeutics, Inc.$KROS
Call Options (obligation to sell)
2022-11-29−3,539→ 0 total
Award
Eloxx Pharmaceuticals, Inc.
Stock Options (Right to Buy)
2022-06-15+20,000→ 20,000 total
Award
Keros Therapeutics, Inc.$KROS
Stock Options (right to buy)
2022-06-01+8,293→ 8,293 total
Award
Keros Therapeutics, Inc.$KROS
Stock Option (right to buy)
2021-06-01+8,293→ 8,293 total
Award
Eloxx Pharmaceuticals, Inc.
Stock Option (Right to Buy)
2021-05-19+20,000→ 20,000 total
Purchase
Eloxx Pharmaceuticals, Inc.
Common Stock
2021-05-13$1.35/sh+592,592→ 616,592 total
Purchase
Eloxx Pharmaceuticals, Inc.
Common Stock
2021-05-13$1.35/sh+1,422,222→ 1,989,551 total
Purchase
Eloxx Pharmaceuticals, Inc.
Common Stock
2021-05-13$1.35/sh+2,630,487→ 3,679,797 total
Purchase
Eloxx Pharmaceuticals, Inc.
Common Stock
2021-05-13$1.35/sh+1,280,624→ 1,791,470 total
Purchase
Keros Therapeutics, Inc.$KROS
Common Stock
2020-11-17$50.00/sh+26,634→ 2,288,151 total
Purchase
Keros Therapeutics, Inc.$KROS
Common Stock
2020-11-17$50.00/sh+14,400→ 1,228,326 total
Purchase
Keros Therapeutics, Inc.$KROS
Common Stock
2020-11-17$50.00/sh+6,000→ 155,262 total
Purchase
Keros Therapeutics, Inc.$KROS
Common Stock
2020-11-17$50.00/sh+12,966→ 1,122,768 total
Award
Eloxx Pharmaceuticals, Inc.
Stock Option (Right to Buy)
2020-05-20+20,000→ 20,000 total
Purchase
Keros Therapeutics, Inc.$KROS
Common Stock
2020-04-13$16.00/sh+194,203→ 2,261,517 total
Conversion
Keros Therapeutics, Inc.$KROS
Common Stock
2020-04-13+88,460→ 1,015,256 total
Conversion
Keros Therapeutics, Inc.$KROS
Series A Preferred Stock
2020-04-13−663,825→ 0 total
Purchase
Keros Therapeutics, Inc.$KROS
Common Stock
2020-04-13$16.00/sh+105,000→ 1,213,926 total
Conversion
Keros Therapeutics, Inc.$KROS
Common Stock
2020-04-13+36,858→ 105,512 total
Purchase
Keros Therapeutics, Inc.$KROS
Common Stock
2020-04-13$16.00/sh+94,546→ 1,109,802 total
Conversion
Keros Therapeutics, Inc.$KROS
Common Stock
2020-04-13+79,653→ 1,108,926 total
Conversion
Keros Therapeutics, Inc.$KROS
Common Stock
2020-04-13+68,654→ 68,654 total
Conversion
Keros Therapeutics, Inc.$KROS
Common Stock
2020-04-13+1,363,542→ 1,734,395 total
Conversion
Keros Therapeutics, Inc.$KROS
Common Stock
2020-04-13+91,538→ 1,029,273 total
Conversion
Keros Therapeutics, Inc.$KROS
Common Stock
2020-04-13+169,307→ 1,903,702 total
Conversion
Keros Therapeutics, Inc.$KROS
Series C Preferred Stock
2020-04-13−36,858→ 0 total
Conversion
Keros Therapeutics, Inc.$KROS
Series C Preferred Stock
2020-04-13−79,653→ 0 total
Conversion
Keros Therapeutics, Inc.$KROS
Series C Preferred Stock
2020-04-13−88,460→ 0 total
Conversion
Keros Therapeutics, Inc.$KROS
Series B-1 Preferred Stock
2020-04-13−68,654→ 0 total
Conversion
Keros Therapeutics, Inc.$KROS
Series A Preferred Stock
2020-04-13−737,226→ 0 total
Conversion
Keros Therapeutics, Inc.$KROS
Common Stock
2020-04-13+82,425→ 926,796 total
Conversion
Keros Therapeutics, Inc.$KROS
Series B-1 Preferred Stock
2020-04-13−82,425→ 0 total
Conversion
Keros Therapeutics, Inc.$KROS
Common Stock
2020-04-13+163,612→ 2,067,314 total
Conversion
Keros Therapeutics, Inc.$KROS
Common Stock
2020-04-13+663,825→ 844,371 total
Conversion
Keros Therapeutics, Inc.$KROS
Series C Preferred Stock
2020-04-13−163,612→ 0 total
Conversion
Keros Therapeutics, Inc.$KROS
Series B-1 Preferred Stock
2020-04-13−91,538→ 0 total

Companies

Recent Filings

Address

200 ROUTE 31 NORTH SUITE 104

FLEMINGTON, NJ, 08822

View on SEC.gov